Krystal Biotech (KRYS) Other Non-Current Liabilities (2018 - 2026)

Krystal Biotech has disclosed Other Non-Current Liabilities across 4 years of filings, most recently posting $5.1 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $5.1 million, up 162.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.1 million (up 162.37% YoY), and the FY2025 annual result was $3.7 million, up 160.75% from the prior year.
• Other Non-Current Liabilities came in at $5.1 million for Q1 2026 at Krystal Biotech, up from $3.7 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $5.1 million in Q1 2026 to a low of $588000.0 in Q2 2024.
• The 3-year median for Other Non-Current Liabilities is $2.4 million (2025), against an average of $2.4 million.
• Peak annual rise in Other Non-Current Liabilities reached 376.19% in 2025, while the deepest fall reached 160.75% in 2025.
• Krystal Biotech's Other Non-Current Liabilities stood at $1.4 million in 2024, then jumped by 160.75% to $3.7 million in 2025, then surged by 38.49% to $5.1 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $5.1 million (Q1 2026), $3.7 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.